ng28ÄϹ¬

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima?/Kisplyx?, ¡°lenvatinib¡±) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven?, ¡°eribulin¡±) will be presented during the European Society for Medical Oncology (ESMO) Congress 2016, taking place in Copenhagen, Denmark, from October 7 – 11.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received license from the European Commission for anticancer agent Kisplyx? ¨‹ (generic name: lenvatinib mesylate, ¡°lenvatinib¡±) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy. Following the United States, Europe marks the second region where lenvatinib has been licensed for the advanced renal cell carcinoma indication.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that it has been selected for a fourth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).

On September 3rd 2016, the Peripheral Neuropathy Forum is successfully held by Eisai China Inc. in Changsha, China.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that it will launch ¡°Chocola BB? Mouth Ulcer Repair Shot¡± (Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. The product is the first oral care spray to be marketed under the Chocola BB brand.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that, at its recent meeting with the U.S. Food and Drug Administration (FDA), the FDA confirmed there was sufficient data to support the advancement of its novel investigational oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III clinical studies. E2609 was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. (Headquarters: Massachusetts, United States, CEO: George A. Scangos, ¡°Biogen¡±) for early Alzheimer¡¯s disease.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received a positive opinion from the European Medicines Agency¡¯s Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate (generic name, ¡°lenvatinib¡±) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF) targeted therapy. If approved, lenvatinib will be launched under the brand name Kisplyx??for this indication.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR?, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ?) for chronic weight management. BELVIQ XR is scheduled for launch in autumn 2016.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. (Location: Mexico City, ¡°Eisai Mexico¡±) has received approval for the antiobesity agent VENESPRI? (lorcaserin hydrochloride, U.S. brand name: BELVIQ?, ¡°lorcaserin¡±) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2?or greater (obese) or 27 kg/m2?or greater (overweight) in the presence of at least one weight-related co-morbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS), the Mexico regulatory authority. Mexico marks the first country in Latin America where lorcaserin is approved. Lorcaserin will be marketed in Mexico under the brand name VENESPRI.

Eco Forum Global Annual Conference Guiyang 2016, Guizhou Green Expo-Big Health & Pharmaceutical Industry Fair and Summit has been held successfully in July 8-10, 2016 in Guiyang City, Guizhou Province. Chairman Mr. Norio Kaneko and General Manager Ms. Yanhui Feng of Eisai (China) Holding Co., Ltd and Eisai China Inc. are invited to attend the Forum and Expo. Eisai China Inc. and Eisai (Liaoning) Pharmaceutical Co., Ltd equip with special show-booths at the Expo.